Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease

This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.

Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 30-75Biological sex: AllType: InterventionalSponsor: Shanghai UniXell Biotechnology Co., LtdUpdated: Jul 29, 2026Locations: 1
Eligibility criteria

Aged between 30 and 75 years, regardless of gender [+6]

The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrom... [+7]

Read more
Status: Not yet recruiting

A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE). The primary objective is to assess the safety, tolerability, and preliminary efficacy of UX-GIP001. This is an open-label, single-arm study. All enrolled participants will receive the active investigational cell therapy. Seizure frequency and safety parameters will be evaluated by comparing post-transplant outcomes to pre-transplant baselines.

Participants needed: 12
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai UniXell Biotechnology Co., LtdUpdated: Jul 27, 2026Locations: 3
Eligibility criteria

Age 18-75 years (inclusive), male or female; [+8]

Epilepsy caused by other/or progressive neurological diseases , or patients - ex... [+9]

Read more